Clinical Trial Update: Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of etelcalcetide (AMG 416) for secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease On Hemodialysis
• Hyperparathyroidism

Drugs mentioned

• Etelcalcetide (etelcalcetide)

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Secondary | Phase 3 | Status: COMPLETED | Results posted: 2017-03-27